We are live on ! Find out more
AEMD icon

Aethlon Medical

7 hedge funds and large institutions have $1.54M invested in Aethlon Medical in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 7 → 7 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.96% less ownership

Funds ownership: 6.01% → 5.05% (-0.96%)

72% less capital inflows, than outflows

Capital inflows: $72.4K | Capital outflows: $263K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AEMD Hedge Fund Activity: Q4 2018 in Review

7 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Aethlon Medical (AEMD) for Q4 2018, worth a combined $1.54M — up 22% from $1.26M a quarter earlier.

Fund positioning in AEMD was balanced in Q4 2018: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Bank of New York Mellon, opening a new position worth an estimated $72.4K. The largest seller was Vanguard Group, cutting an estimated $145K.

  • 7 institutional investors held Aethlon Medical (AEMD) as of Q4 2018, unchanged from Q3 2018.
  • Funds reported $1.54M of Aethlon Medical stock for Q4 2018, up 22% quarter-over-quarter.
  • 1 fund opened new Aethlon Medical positions in Q4 2018 and 1 closed out, a net change of 0 holders.
  • The largest Aethlon Medical buyer in Q4 2018 was Bank of New York Mellon, an estimated $72.4K added.
  • The largest Aethlon Medical seller in Q4 2018 was Vanguard Group, an estimated $145K sold.

Based on aggregated 13F filings for Q4 2018.